IntegraGen S.A. has named Michael E. Dresner as national sales director. He will be responsible for its sales efforts in the U.S. associated with the ARISk(TM) Autism Risk Assessment Test. Mr. Dresner will spearhead sales efforts for the company's ARISk Test, a gender specific, genetic screening test that looks at 65 genetic markers associated with Autism Spectrum Disorder. The test is designed to assess the risk of autism in children from multiplex families--siblings of children with Autism Spectrum Disorder who are 6 to 30 months of age, paving the way to early clinical diagnosis and early intervention, which can lead to significant improvement in IQ scores, language and social skills, and ensure best possible outcomes. The ARISk Test is available only through medical professionals, including pediatricians, developmental pediatricians, child neurologists and autism clinicians. Mr. Dresner brings more than a decade of sales experience in the field of molecular diagnostics testing services. Most recently, he was director of Client and Patient Services for Oxford Immunotec Inc. Before that, he was National Accounts Manager for Anatomical Pathology Instruments and Consumables at Thermo Fisher Scientific, and held several positions at Athena Diagnostics, including Director of Corporate Accounts and National Sales Trainer. Mr. Dresner also served as a sales representative for GlaxoSmithKline Pharmaceuticals and Novartis Pharmaceuticals.